Tauklarify imaging shows whether tau tangles linked to Alzheimer's disease appear on a brain PET scan in 2026. A positive result means the reader saw an Alzheimer's-related tau pattern, while a negative result means that pattern was not seen, but neither result proves the diagnosis alone. Tauklarify is florquinitau F 18 injection, a radioactive tracer given before PET scanning.
Tau tangles are twisted deposits of tau protein that build up inside brain cells. According to Lantheus Holdings, the Food and Drug Administration approved it on Aug. 14, 2026 for adults with cognitive impairment being evaluated for Alzheimer's disease the FDA approval notice.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does a positive or negative scan mean?
- Why can this scan turn positive earlier?
- How often do expert readers agree?
- What should you ask your primary care doctor next?
What does a positive or negative scan mean?
You receive the tracer through an intravenous line, then lie still for the PET scan. American Pharmaceutical Review reports the fluorine-18 tracer binds to tau tangles, and trained readers classify the scan as positive or negative from the signal pattern in the medial temporal lobe and neocortex the American Pharmaceutical Review report. Positive means tangles in an Alzheimer's pattern were visible in those memory and thinking areas.
Negative means that pattern was not visible. The result describes the scan pattern, not your symptoms or your future. A negative scan does not necessarily exclude tau pathology, and a positive scan does not necessarily confirm it under the microscope. Practical Neurology notes performance is lower at earlier stages, so added evaluation is advised when uncertainty remains the Practical Neurology summary.
Why can this scan turn positive earlier?
Older tau tracer rules required tangles beyond the medial temporal lobe before a positive read. Tauklarify can be called positive when tangles are still isolated to the medial temporal lobe. That change matters because the medial temporal lobe supports memory formation. It often shows Alzheimer's tau change first.
A positive result there can reflect an earlier pathologic stage, not advanced spread. For primary care patients, early positivity does not equal early dementia. It gives the care team one more clue about timing and stage. Symptoms, daily function, and other tests still shape the diagnosis.
How often do expert readers agree?
NeurologyLive reports FDA approval rested on two blinded image-reading studies in 617 participants, with independent readers blinded to clinical and amyloid PET results the NeurologyLive analysis. Blinded means the readers did not know the patient's history while scoring the scan. Across five blinded readers, positive agreement ranged from 68 percent to 88 percent, while negative agreement ranged from 93 percent to 99 percent.
Inter-reader agreement was strong, with Fleiss kappa values of 0.92 and 0.86. In plain terms, readers agreed most when calling a scan negative. Positive calls were less consistent, especially at earlier stages. Ask whether your scan was clearly positive, clearly negative, or borderline.
What should you ask your primary care doctor next?
Use the scan as one piece of a broader workup. According to Lantheus Holdings, safety and effectiveness have not been established for non-Alzheimer's tau diseases, so patients with another suspected tau condition should not rely on Tauklarify alone.
Bring your symptom timeline, daily-function changes, medications, amyloid results if you have them, and the full PET report. Ask what stage the pattern suggests and what remains uncertain. Ask whether referral to neurology, more cognitive testing, blood work, or amyloid testing would change the plan.
- Is my result positive, negative, or uncertain, and in which brain areas?
- Does the result fit my symptoms, exam, and other test results?
- What other causes are still possible, and what test comes next?
- Should treatment, trial eligibility, safety planning, or follow-up change now?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Result Interpretation Questions for Primary Care Patients
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Primary Care Patients Can Compare Testing Options
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Result Interpretation Questions for Primary Care Patients
